RadNet, Inc. (RDNT)
NASDAQ: RDNT · IEX Real-Time Price · USD
61.98
+0.01 (0.02%)
Jul 26, 2024, 4:00 PM EDT - Market closed
RadNet Market Cap
RadNet has a market cap or net worth of $4.58 billion as of July 26, 2024. Its market cap has increased by 153.49% in one year.
Market Cap
4.58B
Enterprise Value
5.58B
1-Year Change
153.49%
Ranking
Category
Stock Price
$61.98
Market Cap Chart
Since December 1, 1998, RadNet's market cap has increased from $4.50M to $4.58B, an increase of 101,657.52%. That is a compound annual growth rate of 30.97%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Jul 25, 2024 | 4.58B | 93.94% |
Dec 29, 2023 | 2.36B | 118.56% |
Dec 30, 2022 | 1.08B | -32.87% |
Dec 31, 2021 | 1.61B | 59.23% |
Dec 31, 2020 | 1.01B | -0.98% |
Dec 31, 2019 | 1.02B | 105.33% |
Dec 31, 2018 | 497.00M | 3.33% |
Dec 29, 2017 | 481.00M | 60.49% |
Dec 30, 2016 | 299.70M | 5.16% |
Dec 31, 2015 | 285.00M | -21.85% |
Dec 31, 2014 | 364.70M | 445.14% |
Dec 31, 2013 | 66.90M | -31.03% |
Dec 31, 2012 | 97.00M | 21.71% |
Dec 30, 2011 | 79.70M | -23.59% |
Dec 31, 2010 | 104.30M | 41.33% |
Dec 31, 2009 | 73.80M | -38.45% |
Dec 31, 2008 | 119.90M | -66.04% |
Dec 31, 2007 | 353.10M | 262.15% |
Dec 29, 2006 | 97.50M | 770.54% |
Dec 30, 2005 | 11.20M | -48.62% |
Dec 31, 2004 | 21.80M | -5.22% |
Dec 31, 2003 | 23.00M | 30.68% |
Dec 31, 2002 | 17.60M | -68.23% |
Dec 31, 2001 | 55.40M | 357.85% |
Dec 29, 2000 | 12.10M | 290.32% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
CRISPR Therapeutics AG | 4.89B |
TransMedics Group | 4.81B |
Alkermes | 4.74B |
Apellis Pharmaceuticals | 4.72B |
Haemonetics | 4.62B |
Avidity Biosciences | 4.28B |
Crinetics Pharmaceuticals | 4.21B |
Dyne Therapeutics | 4.18B |